Cargando…

Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis

BACKGROUND: Some of cannabinoids, which are chemical compounds contained in marijuana, are immunosuppressive. One of the receptors, CB receptor 1 (CB(1)), is expressed predominantly by the cells in the central nervous system, whereas CB receptor 2 (CB(2)) is expressed primarily by immune cells. Theo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukuda, Shin, Kohsaka, Hitoshi, Takayasu, Aiko, Yokoyama, Waka, Miyabe, Chie, Miyabe, Yoshishige, Harigai, Masayoshi, Miyasaka, Nobuyuki, Nanki, Toshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243420/ https://www.ncbi.nlm.nih.gov/pubmed/25115332 http://dx.doi.org/10.1186/1471-2474-15-275

Ejemplares similares

Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid–lysophosphatidic acid receptor 1 cascade
por: Miyabe, Yoshishige, et al.
Publicado: (2014)

Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis
por: Kaneko, Kayoko, et al.
Publicado: (2011)

Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice
por: Yokoyama, Waka, et al.
Publicado: (2014)

Targeting the Chemokine System in Rheumatoid Arthritis and Vasculitis
por: Miyabe, Yoshishige, et al.
Publicado: (2020)

Chemokines and chemokine receptors as promising targets in rheumatoid arthritis
por: Murayama, Masanori A., et al.
Publicado: (2023)

Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis
por: Miyabe, Chie, et al.
Publicado: (2019)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
por: Yokoyama-Kokuryo, Waka, et al.
Publicado: (2020)

Pathogens in Vasculitis: Is It Really Idiopathic?
por: Miyabe, Chie, et al.
Publicado: (2021)

Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2022)

Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis
por: Miyabe, Chie, et al.
Publicado: (2021)

Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis
por: Angelini, Alessandro, et al.
Publicado: (2018)

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2021)

Editorial: Targeting the Chemoattractant System in Inflammation
por: Hosoya, Tadashi, et al.
Publicado: (2021)

Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis
por: Nanki, Toshihiro, et al.
Publicado: (2009)

Diagnostic performance of measuring antibodies to the glycopeptidolipid core antigen specific to Mycobacterium avium complex in patients with rheumatoid arthritis: results from a cross-sectional observational study
por: Hirose, Wataru, et al.
Publicado: (2015)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Alteration of microbial composition in the skin and blood in vasculitis
por: Miyata, Ryujin, et al.
Publicado: (2023)

Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial cells
por: Wakamatsu, Kyoko, et al.
Publicado: (2005)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
por: Koike, Ryuji, et al.
Publicado: (2009)

Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial
por: Utsunomiya, Masako, et al.
Publicado: (2017)

Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs
por: Sugihara, Takahiko, et al.
Publicado: (2016)

Cytokine, activation marker, and chemokine receptor expression by individual CD4(+) memory T cells in rheumatoid arthritis synovium
por: Nanki, Toshihiro, et al.
Publicado: (2000)

Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis
por: Yamamoto, Tatsuhiro, et al.
Publicado: (2016)

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
por: Sakai, Ryoko, et al.
Publicado: (2015)

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis: Results from the Institute of Rheumatology Rheumatoid Arthritis cohort study
por: Nakayama, Masanori, et al.
Publicado: (2020)

NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor
por: Kubota, Tetsuo, et al.
Publicado: (2007)

Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts
por: Komano, Yukiko, et al.
Publicado: (2006)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
por: Takeuchi, Tsutomu, et al.
Publicado: (2013)

Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study
por: Sakai, Ryoko, et al.
Publicado: (2022)

Innate immune responses in Behçet disease and relapsing polychondritis
por: Shimizu, Jun, et al.
Publicado: (2023)

An open-label, randomized controlled trial of sulfamethoxazole–trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up
por: Utsunomiya, Masako, et al.
Publicado: (2020)

Interleukin-23 as a therapeutic target for inflammatory myopathy
por: Umezawa, Natsuka, et al.
Publicado: (2018)

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study
por: Miyasaka, Nobuyuki
Publicado: (2008)

Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8
por: Hayashida, Kenji, et al.
Publicado: (2001)

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_91aug6ljloqm0j71r3rkvc8ull